title: CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back.
abstract: The article by Mendel and colleagues, published in the January 1, 2003, issue of Clinical Cancer Research, described their novel preclinical approach to developing a thorough understanding of the exposure-activity relationship for sunitinib, a multitargeted receptor tyrosine kinase inhibitor being developed for oncology therapy. This work successfully set exposure guidelines to identify a biologically active dose in early clinical trials.
authors.affiliation: Translational Medicine, MedImmune, LLC, Gaithersburg, Maryland.
authors.forename: Dirk B
authors.initials: DB
authors.lastname: Mendel
authors.affiliation: Zenith Epigenetics, San Francisco, California.
authors.forename: Julie M
authors.initials: JM
authors.lastname: Cherrington
authors.affiliation: Early Development, Translational and Immuno-Oncology, Pfizer, San Diego, California. douglas.laird@pfizer.com.
authors.forename: A Douglas
authors.initials: AD
authors.lastname: Laird
mesh_terms: D000846:Anniversaries and Special Events; D049674:History, 21st Century; D006801:Humans; D007211:Indoles / Q000266:history / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy* / Q000266:history; D011758:Pyrroles / Q000266:history / Q000627:therapeutic use*; D000077210:Sunitinib
chemical_list: D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib